Safety and efficacy of botox injection in alleviating post-operative pain and improving quality of life in lower extremity limb lengthening and deformity correction

Reggie C Hamdy, Kathleen Montpetit, Joanne Ruck-Gibis, Kelly Thorstad, Ellen Raney, Michael Aiona, Robert Platt, Allen Finley, William Mackenzie, James McCarthy, Unni Narayanan, Reggie C Hamdy, Kathleen Montpetit, Joanne Ruck-Gibis, Kelly Thorstad, Ellen Raney, Michael Aiona, Robert Platt, Allen Finley, William Mackenzie, James McCarthy, Unni Narayanan

Abstract

Background: Distraction osteogenesis is the standard treatment for the management of lower limb length discrepancy of more than 3 cm and bone loss secondary to congenital anomalies, trauma or infection. This technique consists of an osteotomy of the bone to be lengthened, application of an external fixator, followed by gradual and controlled distraction of the bone ends. Although limb lengthening using the Ilizarov distraction osteogenesis principle yields excellent results in most cases, the technique has numerous problems and is not well tolerated by many children. The objective of the current study is to determine if Botulinum Toxin A (BTX-A), which is known to possess both analgesic and paralytic actions, can be used to alleviate post-operative pain and improve the functional outcome of children undergoing distraction osteogenesis.

Methods/design: The study design consists of a multi centre, randomized, double-blinded, placebo-controlled trial. Patients between ages 5-21 years requiring limb lengthening or deformity correction using distraction will be recruited from 6 different sites (Shriners Hospital for Children in Montreal, Honolulu, Philadelphia and Portland as well as DuPont Hospital for Children in Wilmington, Delaware and Hospital for Sick Children in Toronto, Ont). Approximately 150 subjects will be recruited over 2 years and will be randomized to either receive 10 units per Kg of BTX-A or normal saline (control group) intraoperatively following the surgery. Functional outcome effects will be assessed using pain scores, medication dosages, range of motion, flexibility, strength, mobility function and quality of life of the patient. IRB approval was obtained from all sites and adverse reactions will be monitored vigorously and reported to IRB, FDA and Health Canada.

Discussion: BTX-A injection has been widely used world wide with no major side effects reported. However, to the best of our knowledge, this is the first time BTX-A is being used under the context of limb lengthening and deformity correction.

Trial registration: NCT00412035.

References

    1. McCullough N. The Child With a Limb Deficiency. In: Herring JA, Birch JG, editor. Shriners Hospital for Crippled Children Symposium. American Academy of Orthopaedic Surgeons; 1997.
    1. Codivilla A. On the means of lengthening in the lower limbs, the muscles and tissues, which are shortened through deformity. 1904. Clin Orthop Relat Res. 1994;301:4–9.
    1. Karger C, Guille JT, Bowen JR. Lengthening of congenital lower limb deficiencies. Clin Orthop. 1993:236–45.
    1. Ilizarov GA. The tension-stress effect of the genesis and growth of tissues. Part I. The influence of stability of fixation and soft-tissue preservation. Clin Orthop. 1989;238:249–81.
    1. Ilizarov GA. The tension-stress effect on the genesis and growth of tissues: Part II. The influence of the rate and frequency of distraction. Clin Orthop. 1989;239:263–85.
    1. Noonan Kenneth J, Leyes Manuel, Forriol Francisco, Canadell Jose. Distraction Osteogenesis of the Lower Extremity with Use of Monolateral External Fixation. J Bone Joint Surg. 1981;6:793–806.
    1. Maffulli Nicola, Lombari Corrado, Matarazzo Lorenzo, Nele Ubaldo, Pagnotta Gaetano, Fixsen John A. A review of 240 patients undergoing distraction osteogenesis for congenital post-traumatic or post infective lower limb length discrepancy. Journal of the American College of Surgeons. 1996;182:394–402.
    1. Paley D. Current techniques of limb lengthening. J Pediatri Orthop. 1988;8:73–92.
    1. De Bastiani G, Aldegheri R, Renzi-Brivio L, Trivella G. Limb lengthening by callus distraction (callotasis) J Pediatr Orthop. 1987;7:129–134.
    1. Garcia-Cimbrelo , Eduardo , Olsen Bernardo, Ruiz-Yague Manuel, Fernandez-Baillo N, Manuera-Martinez L. Ilizarov technique. results and difficulties. Clin Ortho Rel Res. 1992;283:116–123.
    1. Paley D. Problems, obstacles, and complications of limb lengthening by the Ilizarov technique. Clin Orthop Rel Res. 1990;250:81–104.
    1. Eldridge JC, Bell DF. Problems with substantial limb lengthening. Orthop Clin North Am. 1991;22:625–631.
    1. Rauch F, Lauzier D, Travers R, Glorieux F, Hamdy R. Effects of locally applied TGF-β1 on distraction osteogenesis in a rabbit limb lengthening model. Bone. 2000;26:619–624. doi: 10.1016/S8756-3282(00)00283-0.
    1. Hamdy R, Amako M, Beckman L, Kawaguchi M, Rauch F, Lauzier D, Steffen T. Effects of osteogenic protein-1 on distraction osteogenesis in rabbits. Bone. 2003;33:248–253. doi: 10.1016/S8756-3282(03)00154-6.
    1. Young N, Bell DF, Anthony A. Pediatric pain patterns during Ilizarov treatment of limb length discrepancy and angular deformity. J Pediatr Orthop. 1994;14:352–357.
    1. Lindsey CA, Makarov MR, Shoemaker S, Birch JG, Buschang Peter PH, Cherkashin AM, Welch RD, Samchukov ML. The effect of the amount of limb lengthening on skeletal muscle. Clin Orthop Rel Res. 2002;402:278–287. doi: 10.1097/00003086-200209000-00028.
    1. Makarov Marina R, Kochutina Ludmila N, Samchukov Mikhail L, Birch John G, Welch Robert D. Effect of rhythm and level of distraction on muscle structure. Clin Orthop Rel Res. 2001;384:250–264. doi: 10.1097/00003086-200103000-00030.
    1. Galardi G, Comi G, Lozza L, Marchettini P, Novarina M, Facchini R, Paronzini A. Peripheral nerve damage during limb lengthening. neurophysiology in five cases of bilateral tibial lengthening. J Bone Joint Surg [Br] 1990;72:121–124.
    1. Young NL, Davis RJ, Bell DF, Redmond DM. Electromyographic and nerve conduction changes after tibial lengthening by the Ilizarov method. J Pediatr Orthop. 1993;13:473–477.
    1. Kaljumäe Ü, Märtson A, Haviko T, Häanninen O. The effect of lengthening of the femur on the extensors of the knee. an electromyographic study. J Bone Joint Surg [Am] 1995;77:247–250.
    1. Bernd F, Neuen-Jacob E, Marius M, Arnd L, Wolfgang R. Morphometric analysis of canine skeletal muscles following experimental callus distraction according to the ilizarov method. J Orthop Res. 2000;18:620–628. doi: 10.1002/jor.1100180415.
    1. Fink B, Von Giesen HJ, Wilcke C, Lehmann J, Sager M, Schmielau G, Rüther W. Electromyographically Evident changes in skeletal muscles during tibial lengthening in dogs using the ilizarov method. Arch Orthop Trauma Surg. 2000;120:79–83. doi: 10.1007/s004020050468.
    1. Aoki R, Martin K. Pharmacology in pain relief. In: Childers MK, editor. Botulinum Toxin Type A In Pain Management A Clinician's Guide. 2. Academic Information Systems; 2002. pp. 31–40.
    1. Jankovic J, Vuong MA, Ahsan J. Comparison of efficacy and immunogenicity of originial versus current botulinum toxin in cervical dystonia. Neurology. 2003;60:1186–1188.
    1. Lew Mark F. Review of the fda-approved uses of botolinum toxins, including data suggesting efficacy in pain reduction. The Clinical Journal of Pain. 2002:142–146.
    1. Anderson ER., Jr Proper dose, preparation, and storage of botulinum neurotoxin serotype A. Am J Health Syst Pharm. 2004:24–29.
    1. Odergren T, Hjaltason H, Kaakkola S, Solders G, Hanko J, Fehling C, Marttila RJ, Lundh H, Gedin S, Westergren I, Richardson A, Dott C, Cohen H. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry. 1998;64:6–12.
    1. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, Kessler KR, Ceballos-Bauman AO, Ohly A, Oertel W, Kunig- the German Dystonia Study Group (GDSG) What is the optimal dose of botolinum toxin A in the treatment of cervical Dystonia? Results of a double blind, placebo controlled, dose ranging study using Dysport. J Neurol Neurosurg Psychiatry. 1998;64:13–17.
    1. Lang AM. Botolinum toxin type A therapy in chronic pain disorders. Arch Phys Med Rehabil. 2003:69–73. doi: 10.1053/apmr.2003.50121.
    1. Argoff CE. A focused review on the use of botolinum toxins for neuropathic pain. The Clinical Journal of Pain. 2002:177–181.
    1. Setler PE. Therapeutic use of botolinum toxins: background and history. The Clinical Journal of Pain. 2002:119–124.
    1. Loder E, Biondi D. Use of botolinum toxins for chronic headaches: a focused review. The Clinical Journal of Pain. 2002:169–176.
    1. Difazio Mark, Jabbari Bahman. A focused review of the use of botulinum toxins for low back pain. The Clinical Journal of Pain. 2002:155–162.
    1. Freund Brian J, Schwartz Marvin. Use of botulinum toxin in chronic whiplash-associated disorder. The Clinical Journal of Pain. 2002:163–168.
    1. Buitrago MM, Koolwiji I. Botulinum toxin for spasticity after stoke. The New England Journal of Medicine. 2003;348:258–259. doi: 10.1056/NEJM200301163480316.
    1. Wissel J, Masuhr F, Schelosky L, Edersbach G, Poewe W. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Movement Disorders. 1997;12:722–726. doi: 10.1002/mds.870120516.
    1. Wollina U, Konrad H. Botulinum toxin a in anal fissures: a modified technique. European Academy of Dermatology and Venereology. 2002;16:469–471. doi: 10.1046/j.1468-3083.2002.00490.x.
    1. Walton JM, Tougas G. Botulinum Toxin Use in Pediatric Esophageal Achalasia: A Case Report (1996), From the Division of Surgery at the Children's Hospital, and the Gastrointestinal Disease Unit, McMaster University Medical Center, Hamilton, Ontario. Presented at the 28th Annual Meeting of the Canadian Association of Paediatric Surgeons, Halifax, Nova Scotia, August 18–20.
    1. Freund BJ, Schwartz M. Relief of tension-type headache symptoms in subjects with temporomandibular disorders treated with botulinum toxin-A. Headache. 2002;42:1033–1037. doi: 10.1046/j.1526-4610.2002.02234.x.
    1. Sevim S, Dogu O, Kaleagasi H. Botulinum toxin-A therapy for palmar and plantar hyperhidrosis. Acta neurolo Belg. 2002;102:167–170.
    1. Fishman LM, Anderson C, Rosner B. Botox and physical therapy in the treatment of piriformis syndrome. American Journal of Physical Medicine & Rehabilitation. 2002;81:936–942. doi: 10.1097/00002060-200212000-00009.
    1. Evers S, Rahmann A, Vollmer-Haase J, Husstedt I-W. Treatment of headache with botulinum toxin-A, a review according to evidence-based medicine criteria. Blackwell Science Ltd Cephalagia. 2002;22:699–710.
    1. Micheli F, Scorticati MC, Raina G. Beneficial effects of botulinum toxin type A for patients with painful tic convulsif. Clinical Neuropharmacology. 2002;25:260–262. doi: 10.1097/00002826-200209000-00006.
    1. Bjerkhoel A, Trobbe O. Frey's Syndrome: Treatment with Botulinum Toxin. J Laryngol Otol. 1997;111:839–844.
    1. Sampalo C, Ferreira JJ, Pinto AA, Crespo M, Ferro JM, Castro-Calda A. Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients. Clinical Rehabilitation. 1997;11:3–7.
    1. Goldstein E. Presentation at the annual AACPDM. Montreal. 2003.
    1. Francisco GE. Botulinum toxin: dosing and dilution. Am J Phys Med Rehabil. 2004:30–37. doi: 10.1097/01.PHM.0000141128.62598.81.
    1. Lee LR, Chuan YC, Yang BJ, Hsu MJ, Liu YH. Botulinum toxin for lower limb spasticity in children with cerebral palsy: a single-blinded trial comparing dilution techniques. Am J Phys Med Rehabil. 2004;83:766–73. doi: 10.1097/01.PHM.0000137314.38806.95.
    1. Bakheit AM, Severa S, Cosgrove A, Morton R, Rousso SH, Doderlein L, Lin JP. Safety profile and efficacy of botulinum toxin A (dysporta) in children with muscle spasticity. Dev Med Child Neurol. 2001;43:234–238. doi: 10.1017/S0012162201000445.
    1. Bakheit AMO. Botulinum toxin in the management of childhood muscle spasticity: comparison of clinical practice of 17 treatment centres. Eur J Neurol. 2003;10:415–9. doi: 10.1046/j.1468-1331.2003.00619.x.
    1. Brin MF, Aoki KR. Botulinum Toxin Type A. Pharmacology in Spasticity, Etiology, Evaluation, Management and the Role of Botulinum Toxin. In: Mayer NlH, Simpson DM, editor. We Move Worldwide Education. 2002. p. 111.
    1. Mancini F, Sandrini G, Moglia A, Nappi G, Pacchetti C. A randomised, double-blind, dose-ranging study to evaluate efficacy and safety of three doses of botulinum toxin type A (Botox) for the treatment of spastic foot. Neurol Sci. 2005;26:26–31. doi: 10.1007/s10072-005-0378-9.
    1. Steenbeck D, Meester-Delver A, Becher JG, Lankhorst GJ. The effect of botulinum toxin type A treatment of the lower extremity on the level of functional abilities in children with cerebral palsy: evaluation with goal attainment scaling. Clin Rehabil. 2005;19:274–82. doi: 10.1191/0269215505cr859oa.
    1. Rousseaux M, Compere S, Launay MJ, Kozlowski O. Variability and predictability of functional efficacy of botulinum toxin injection in leg spastic muscles. J Neurol Sci. 2005;232:51–57. doi: 10.1016/j.jns.2005.01.009.
    1. Lowe NJ, Ascher B, Heckmann M, Kumar C, Fraczek S, Eadie N, Btox Facial Aesthetics Study Team Double-blind, randomized, placebo-controlled, dose-response study of the safety of Botulinum toxin type A in subjects with crow's feet. Dermatol Surg. 2005;31:257–62.
    1. Satila H, Lisalo T, Pietikainen T, Seppanen RL, Salo M, Koivikko M, Autti-Ramo I, Haataja R. Botulinum toxin treatment of spastic equinus in cerebral palsy: a randomized trial comparing two injection sites. Am J Phys Med Rehabil. 2005;84:355–65. doi: 10.1097/.
    1. Pidcock FS, Fish DE, Johnson-Greene D, Borras I, McGready J, Silberstein CE. Hip migration percentage in children with cerebral palsy treated with botulinum toxin type A. Arch Phys Med Rehabil. 2005;86:431–5. doi: 10.1016/j.apmr.2004.03.034.
    1. Charles PD. Botulinum neurotoxin serotype A: a clinical update on non-cosmetic uses. Am J Health Syst Pharm. 2004:11–23.
    1. Naumann M, Jankovic J. Safety of botulinum toxin type A : a systematic review and meta-analysis. Curr Med Res Opin. 2004;20:981–90. doi: 10.1185/030079904125003962.
    1. Klein AW. Complications with the use of botulinum toxin. Dermatol Clinc. 2004;22:197–205. doi: 10.1016/S0733-8635(03)00122-0.
    1. Jankovic J. Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004;75:951–957. doi: 10.1136/jnnp.2003.034702.
    1. Jankovic J, Brin MF. Therapeutic uses of botulinum toxin (review) J Med. 1991;324:1186–1194.
    1. Tsui JK, Eisen A, Mak E, Carruthers MI, Scott A, Calne DB. A pilot study on the use of botuinum toxin in spasmodic torticolis. Can J Neurol Sci. 1985;12:314–316.
    1. Schulte-Matler WJ, Blersch W, Przywara S, et al. Botulinum Toxin A and the Cutaneous Nociception in Humans [Abstract] Arch Pharmacol. 2002;365:R39.
    1. Cui M, Aoki KR. Botulinum toxin type A (BTX-A) reduces inflammatory pain in the rat formalin model [abstract] Cephalalgia. 2000;20:s414. doi: 10.1046/j.1468-2982.2000.020004414.x.
    1. Aoki RK. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache. 2003:9–15. doi: 10.1046/j.1526-4610.43.7s.3.x.
    1. Arezzo JC. Possible mechanisms for the effects of botulinum toxin on pain. Clin J Pain. 2002:S125–S132. doi: 10.1097/00002508-200211001-00003.
    1. Sheean G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Current Pain and Headache Reports. 2002;6:456–469. doi: 10.1007/s11916-002-0065-y.
    1. Juan FJ. Use of botulinum toxin-A for musculoskeletal pain in patients with whiplash associated disorders. Musculoskelet Disord. 2004;5:5. doi: 10.1186/1471-2474-5-5.
    1. Bach-Rojecky L, Lackovic Z. Antinociceptive effect of botulinum toxin type A in rat model of carrageenan and capsaicin induced pain. Croat Med J. 2005;46:201–8.
    1. Bentsianov B, Zalvan C, Blitzer A. Noncosmetic uses of botulinum toxin. Dermatol Clin. 2004;22:187–95. doi: 10.1016/S0733-8635(03)00020-2.
    1. Barwood S, Bailieu C, Boyd R, Brereton K, Low J, Nattrass G, Graham HK. Analgesic effects of botuinum toxin A: A randomized, placebo-controlled clinical trial. Dev Med Child Neurol. 2000;42:116–121. doi: 10.1017/S0012162200000220.
    1. Devereaux PJ, McKee MD, Yusuf S. Methodologic issues in randomized controlled trials of surgical interventions. Clin Orthop Rel Res. 2003;413:25–32. doi: 10.1097/01.blo.0000080539.81794.54.
    1. Brighton B, Bhandari M, Tornetta Pl, Felson DT. Part I. methologic issues in the design of orthopaedic studies. Clin Orthop Rel Res. 2003;414:19–24.
    1. McCaffrey M, Paseco C. Pain. Clinical Manual, Mosby Inc; 1999.
    1. Savedra MC, Tesler MD, Holzemer WL, Ward JA. Adolescent pediatric pain tool (APPT) preliminary user's manual. San Francisco: University of California, San Francisco, School of Nursing; 1989.
    1. Savedra MC, Tesler MD, Holzemer WL, Wilkie DJ, Ward JA. Pain location: validity and relaibility of body outline markings by hospitalized children and adolescents. Res Nurs Health. 1989;12:307–14. doi: 10.1002/nur.4770120506.
    1. Varni JW, Seid M, Kurtin PS. The PedsQl 4.0: reliabiliy and validity of the pediatric quality of life Inventory Version 4.0 generic core scales in healthy and paitent populations. Medical Care. 2001;39:800–812. doi: 10.1097/00005650-200108000-00006.
    1. Stein R, Jessop DJ. The impact on family scale revisited: further psychometric data. J Dev Behav Pediatr. 2003;24:9–16.
    1. Morgan GA, Harmon RJ, Maslin-Cote CA. Mastery motivation: it's defintion and measurement. Early education and Development. 1990;1:318–339. doi: 10.1207/s15566935eed0105_1.
    1. Morgan GA, Leech NL, Barrett KC. The Dimensions of Mastery Questionnaire: a manual about its development, psychometrics and use. University of Colorado School of Medicine; 2000.
    1. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35:549–556. doi: 10.2307/2530245.
    1. Piantadosi S. Clinical Trials. New York: Wiley; 1997.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner